Cassady Schiller Wealth Management’s Royalty Pharma RPRX Stock Holding History

Cassady Schiller Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.4K	Buy	+55	New	+$1.46K	﹤0.01%	694

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cassady Schiller Wealth Management's RPRX Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Royalty Pharma (RPRX) in Q4 2024: 55 shares worth $1.4K. The stake represents ﹤0.01% of the portfolio and ranks #694 among its holdings.

416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

Cassady Schiller Wealth Management held 55 shares of Royalty Pharma worth $1.4K as of Q4 2024.
Royalty Pharma was a new Cassady Schiller Wealth Management position in Q4 2024.
Royalty Pharma made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #694 holding.
416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.